Technetium-99m-alendronate: a new radiopharmaceutical for bone scanning
Arch. med. res
; 27(4): 481-3, 1996. ilus
Article
em En
| LILACS
| ID: lil-200350
Biblioteca responsável:
MX1.1
RESUMO
The purpose of this paper is to report the preparation of a new technetium-99m-radiopharmaceutical for bone scanning. The chelating agent for99mTc is a new bisphosphonate, alendronate, 4-amino-1-hydroxy-butylidene-1,1-bisphosphonate (ABP) used as a treatment for osteoporosis. ABP, because of its amino group, seems to be better suited to form a strong and stable complex with technetium-99m and therefore might be better than 99mTc-etidronate (HEDP) or 99mTc-medronate (MDP) for bone scanning. A sterile dry kit containing APB, a reducing agent and a stabilizer was prepared. The parameters studied were molar concentrations, pH, shelf life, labeling efficiency and radiochemical purity. the oven dried sterile kit was formulated with 5 mg ABP, 0.25 mg stannous fluoride and 0.025 mg gentisic acid at pH2.5-3.5. The labeling efficiency with 20 - 1500 MBq of pertechnetate (99mTcO4-) was over 95 percent at room temperature and was stable for 5 h. Technetium-99m-alendronate was tested in two rabbits and it proved to be a promising new radiopharmaceutical for bone scanning. Work is underway to study underway to study 99m-Tc-ABP biodistribution in a statistically significant number of laboratory animals and, later on, to determine radiopharmacokinetic parameters in normal volunteers
Buscar no Google
Base de dados:
LILACS
Assunto principal:
Osteoporose
/
Radioquímica
/
Osso e Ossos
/
Microscopia Eletrônica de Varredura
/
Compostos de Tecnécio
/
Descalcificação Patológica
/
Difosfonatos
Idioma:
En
Ano de publicação:
1996
Tipo de documento:
Article